Published • loading... • Updated
Wegovy Has the Potential to Reduce the Risk of Migraines and Depression in Menopausal Women
Summary by viva.co.id
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
In studies, women using Wegovy, which contains the active ingredient semaglutide, experienced a 42-45% lower risk of migraines compared to those using only menopausal hormone therapy.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
